Quantification of Elastin Markers Synthesis in Williams-Beuren Syndrome and 7q11.23 Micro-duplication Syndrome
试验速览
- 阶段
- 不适用
- 入组人数
- 90
- 试验地点
- 2
- 主要终点
- Plasma level of elastin peptides (PE)
研究概览
简要总结
Introduction: Williams-Beuren syndrome is a rare genetic disorder caused by a 7q11.23 microdeletion. The phenotype associates vasculopathy (arterial stenosis, hypertension), dimorphism and intellectual disability. Microdeletion includes several genes: ELN encodes for elastin and the haplo-insufficiency (only 1 functional copy) causes vasculopathy.
The primary objective is to quantify plasma and urinary levels of elastin peptides in Williams-Beuren patients and 7q11.23 micro-duplication syndrome patients in order to correlate the levels of these markers with the number of copies of ELN gene (proportional positive relationship "gene copy number - circulating levels of markers) Materials and Methods: This prospective study will be carried out in Lyon at the "Hôpital Femme-Mère-Enfant" for 2 years. 3 groups of patients will be studied: Williams-Beuren patients (N=20), micro-duplication 7q11.23 syndrome patients (N=10) and healthy patients (N=60). Subjects will be followed for 1 day.
Clinical examination (weight, height, blood pressure) and biological sample collection (blood and urine sample) will be carry out for Williams Beuren and micro-duplication 7q11.23 patients group. A large majority of visits will be part of patients' usual care. A large part of patients are systematically seen in consultation once a year. For healthy group, only biological sample collection will be carry out. The PE concentrations will be assessed and compared between the three groups of patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 3 Months 至 60 Years(Child, Adult)
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age : from 3 months to 60 years old
- •Williams Beuren group : Diagnosis confirmed with FISH
- •Micro-duplication 7q11.23 group : Diagnosis confirmed with CGHarray
- •Healthy Group : no cardiovascular and neurological medical history
- •Informed consent
排除标准
- •No social insurance
- •Subject under judicial protection
- •Subject participating in another research including an exclusion period still in progress
研究组 & 干预措施
Williams Beuren
Subjects aged from 3 months to 60 years with a diagnosis confirmed with FISH of Williams Beuren syndrome.
干预措施: Physical examination and Urine and blood samples (Biological)
Micro-duplication 7q11.23
Subjects aged from 3 months to 60 years with a diagnosis confirmed with CGHarray of micro-duplication 7q11.23 syndrome.
干预措施: Physical examination and Urine and blood samples (Biological)
Healthy Group
Subjects without cardiovascular and neurological medical history.
干预措施: Urine and blood samples (Biological)
结局指标
主要结局
Plasma level of elastin peptides (PE)
时间窗: 1 day
To quantify plasma level of elastin peptides in participants in order to correlate the levels of these markers with the number of copies of ELN gene (proportional positive relationship "gene copy number - circulating levels of markers). The primary endpoint will be assessed by measuring the blood level of PE between groups
Urinary level of elastin peptides (PE)
时间窗: 1 day
To quantify urinary level of elastin peptides in participants in order to correlate the levels of these markers with the number of copies of ELN gene (proportional positive relationship "gene copy number - circulating levels of markers). The primary endpoint will be assessed by measuring the urinary level of PE between groups
次要结局
- Correlation between blood level of PE and cardiovascular involvement in patients.(1 day)
- Blood level of PE in treated and untreated minoxidil patients(1 day)
- Correlation between urinary level of PE and cardiovascular involvement in patients.(1 day)
- Urinary level of PE in treated and untreated minoxidil patients(1 day)
